Glutaraldehyde
RTECS #
MA2450000
CAS #
Updated
December 2018
Molecular Weight
100.13
Molecular Formula
C5H8O2
Synonyms
1,3-Diformylpropane
1,5-Pentanedial
1,5-Pentanedione
Aldehyd glutarowy (Polish)
Cidex
Glutaral
Glutaraldehyd (Czech)
Glutaraldehyde (ACGIH)
Glutardialdehyde
Glutaric dialdehyde
NCI-C55425
Potentiated acid glutaraldehyde
Sonacide
1,5-Pentanedial
1,5-Pentanedione
Aldehyd glutarowy (Polish)
Cidex
Glutaral
Glutaraldehyd (Czech)
Glutaraldehyde (ACGIH)
Glutardialdehyde
Glutaric dialdehyde
NCI-C55425
Potentiated acid glutaraldehyde
Sonacide
Skin and Eye Irritation and References
| Route/Organism | Dose | Effect | Reference |
|---|---|---|---|
| eye /rabbit | 1 mg | severe | UCDS** 1/30/1970 |
| eye /rabbit | 250 µg/24H | severe | 85JCAE -,272,1986 |
| eye /woman | 200 ppb | TOXID9 72,292,2003 | |
| skin /human | 1%/2D | CODEDG 61,163,2009 | |
| skin /human | 6 mg/3D- intermittent | severe | 85DKA8 -,127,1977 |
| skin /mouse | 2.5%/3D | TXCYAC 279,115,2011 | |
| skin /rabbit | 13 mg open irritation test | mild | UCDS** 1/30/1970 |
| skin /rabbit | 2 mg/24H | severe | 85JCAE -,272,1986 |
Mutation Data and Reference
| System Test | Route/Organism/Tissue | Dose | Reference |
|---|---|---|---|
| Cytogenetic Analysis | ovary/hamster | 160 µg/L | ENMUDM 7,1,1985 |
| DNA Damage | lymphocyte/human | 10 µmol/L | EMMUEG 17(Suppl 19),71,1991 |
| DNA Damage | leukocyte/human | 5 µmol/L | MUREAV 468,93,2000 |
| DNA Damage | fibroblast/hamster | 20 µmol/L/1H | MUREAV 649,146,2008 |
| DNA Damage | leukocyte/chicken | 8 pph | CELLB5 5,45,1975 |
| DNA Damage | lymphocyte/mammal (species unspecified) | 2500 µmol/L | MUREAV 283,131,1992 |
| DNA Damage | fibroblast/hamster | 2500 ppm | SFCRAO 23,346,1970 |
| DNA repair | /Bacillus subtilis | 1 mg/L | MUREAV 193,21,1988 |
| micronucleus test | fibroblast/hamster | 10 µmol/L/1H | MUREAV 649,146,2008 |
| mutation in mammalian somatic cells | lymphocyte/mouse | 8 mg/L | EMMUEG 11,91,1988 |
| mutation in microorganisms | /Salmonella typhimurium | 500 nmol/L (+enzymatic activation step) | MUREAV 148,25,1985 |
| mutation in microorganisms | /Salmonella typhimurium | 150 µg/plate (-enzymatic activation step) | ENMUDM 5(Suppl 1),3,1983 |
| mutation in microorganisms | /Escherichia coli | 62500 ng/plate (-enzymatic activation step) | MUREAV 412,17,1998 |
| mutation in microorganisms | /Salmonella typhimurium | 6.25 µg/plate/48H (-enzymatic activation step) | MUREAV 747,36,2012 |
| mutation in microorganisms | /Salmonella typhimurium | 6.25 mg/L/49H (-enzymatic activation step) | MUREAV 747,36,2012 |
| mutation in microorganisms | /Salmonella typhimurium | 3.125 mg/L/49H (+enzymatic activation step) | MUREAV 747,36,2012 |
| mutation in microorganisms | /Salmonella typhimurium | 6.25 µg/plate/48H (+enzymatic activation step) | MUREAV 747,36,2012 |
| mutation in microorganisms | /Escherichia coli | 12.5 µg/plate/48H (-enzymatic activation step) | MUREAV 747,36,2012 |
| mutation in microorganisms | /Escherichia coli | 12.5 mg/L/49H (-enzymatic activation step) | MUREAV 747,36,2012 |
| mutation in microorganisms | /Escherichia coli | 25 µg/plate/48H (+enzymatic activation step) | MUREAV 747,36,2012 |
| mutation in microorganisms | /Escherichia coli | 12.5 mg/L/49H (+enzymatic activation step) | MUREAV 747,36,2012 |
| mutation in microorganisms | /Salmonella typhimurium | 0.025 mg/plate/3D (-enzymatic activation step) | MUREAV 521,19,2002 |
| mutation in microorganisms | /Salmonella typhimurium | 25 µg/plate/72H (-enzymatic activation step) | MUTAEX 15,495,2000 |
| other mutation test systems | other cell types/non-mammalian species | 50 mmol/L | ECREAL 95,233,1975 |
| sister chromatid exchange | ovary/hamster | 110 µg/L | ENMUDM 7,1,1985 |
| sister chromatid exchange | fibroblast/hamster | 10 µmol/L/1H | MUREAV 649,146,2008 |
Reproductive Effects Data and References
| Route/Organism | Dose | Effect | Reference |
|---|---|---|---|
| oral/rat | 875 mg/kg (35D male) | Reproductive: Paternal effects: Testes, epididymis, sperm duct Reproductive: Paternal effects: Prostate, seminal vesicle, Cowper's gland, accessory glands | OYYAA2 12,11,1976 |
| oral/rat | 4370 mg/kg (35D prior to copulation) | Reproductive: Maternal effects: Uterus, cervix, vagina | OYYAA2 12,11,1976 |
| oral/rat | 1 gm/kg (6-15D pregnant) | Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus) | TOLED5 63,147,1992 |
| oral/mouse | 50 gm/kg (6-15D pregnant) | Reproductive: Specific developmental abnormalities: Central nervous system Reproductive: Specific developmental abnormalities: Craniofacial (including nose and tongue) Reproductive: Specific developmental abnormalities: Musculoskeletal system | TJADAB 22,51,1980 |
| oral/mouse | 8 gm/kg (6-15D pregnant) | Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus) | TJADAB 22,51,1980 |
| oral/rabbit | 585 mg/kg (7-19D pregnant) | Reproductive: Other effects on female Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants) Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus) | NTIS** OTS0526410 |
| oral/rat | 5.3 gm/kg (84D male/70D pre-4W after birth) | Reproductive: Effects on newborn: Growth statistics (e.g., reduced weight gain) Reproductive: Effects on newborn: Other postnatal measures or effects Reproductive: Effects on newborn: Delayed effects | JTEHD6 61,107,2000 |
| oral/rat | 167.4 mg/kg (multigenerations) | Reproductive: Effects on newborn: Growth statistics (e.g., reduced weight gain) Reproductive: Effects on newborn: Delayed effects | JTEHD6 61,107,2000 |
Tumorigenic Data and References
| Route/Organism | Dose | Effect | Reference |
|---|---|---|---|
| oral/rat | lowest published toxic dose: 2912 mg/kg/104W- continuous | Tumorigenic: Carcinogenic by RTECS criteria Blood: Leukemia Tumorigenic: Increased incidence of tumors in susceptible strains | TXCYAC 175,177,2002 |
| oral/rat | lowest published toxic dose: 2912 mg/kg/104W- intermittent | Tumorigenic: Carcinogenic by RTECS criteria Blood: Leukemia Tumorigenic: Increased incidence of tumors in susceptible strains | TXCYAC 175,177,2002 |
Acute Toxicity Data and References
| Route/Organism | Dose | Effect | Reference |
|---|---|---|---|
| In Vitro/Human, leukemia cells | Inhibitor Concentration (5 percent kill): 506 mg/L/30M | In Vitro Toxicity Studies: Cell counting | TIVIEQ 27,857,2013 |
| In Vitro/Human, leukemia cells | Inhibitor Concentration Low: 1.40 mg/L/30M | In Vitro Toxicity Studies: Other assays | TIVIEQ 27,857,2013 |
| In Vitro/Human, leukemia cells | Inhibitor Concentration (25 percent kill): 5.3 mg/L/24H | In Vitro Toxicity Studies: Cell viability (dye exclusion): trypan blue assay etc. | TIVIEQ 26,1150,2012 |
| In Vitro/Human, leukemia cells | Inhibitor Concentration (50 percent kill): 2.78 mg/L/24H | In Vitro Toxicity Studies: Other assays | TIVIEQ 26,1150,2012 |
| In Vitro/Human, leukemia cells | Inhibitor Concentration (25 percent kill): 35 mg/L/48H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 30,318,2015 |
| In Vitro/Human, leukemia cells | Inhibitor Concentration Low: 35 mg/L/48H | Immunological Including Allergic: Increase in cellular immune response | TIVIEQ 30,318,2015 |
| In Vitro/Human, leukemia cells | Inhibitor Concentration Low: 35 mg/L/24H | Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | TIVIEQ 30,318,2015 |
| In Vitro/Human, lung | Inhibitor Concentration (20 percent kill): 0.19 mmol/L | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 30,274,2015 |
| In Vitro/Human, lung | Inhibitor Concentration (50 percent kill): 7.8 gm/L/3H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 27,174,2013 |
| In Vitro/Human, lung | Inhibitor Concentration (50 percent kill): 0.6 gm/L/24H | In Vitro Toxicity Studies: Cell membrane integrity: Cytoplasmic enzymes leakage (lactate dehydrogenase, ATP enzymes etc.) | TIVIEQ 27,174,2013 |
| In Vitro/Human, lung | Inhibitor Concentration (50 percent kill): 0.8 gm/L/24H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 27,174,2013 |
| In Vitro/Human, lung | Inhibitor Concentration (50 percent kill): 0.6 gm/L/24H | In Vitro Toxicity Studies: Other assays | TIVIEQ 27,174,2013 |
| In Vitro/Human, lung tumor | Inhibitor Concentration (50 percent kill): 1.5 gm/L/24H | In Vitro Toxicity Studies: Cell membrane integrity: Cytoplasmic enzymes leakage (lactate dehydrogenase, ATP enzymes etc.) | TIVIEQ 27,174,2013 |
| In Vitro/Human, lung tumor | Inhibitor Concentration (50 percent kill): 1.4 gm/L/24H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 27,174,2013 |
| In Vitro/Human, lymphocyte | Inhibitor Concentration (30 percent kill): >200 mg/L/45H | In Vitro Toxicity Studies: Cell viability (dye exclusion): trypan blue assay etc. | TIVIEQ 29,901,2015 |
| In Vitro/Human, lymphocyte | Inhibitor Concentration (50 percent kill): 83 mg/L/45H | In Vitro Toxicity Studies: Other assays | TIVIEQ 29,901,2015 |
| In Vitro/Human, monocyte | Inhibitor Concentration Low: 17.8 mg/L/2H | In Vitro Toxicity Studies: Other assays | TIVIEQ 27,1233,2013 |
| In Vitro/Human, monocyte | Inhibitor Concentration (20 percent kill): 69 µmol/L/24H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TOLED5 199,51,2010 |
| In Vitro/Human, monocyte | Inhibitor Concentration (20 percent kill): 69 µmol/L/2H | In Vitro Toxicity Studies: Other assays | TOLED5 199,51,2010 |
| In Vitro/Human, skin | Inhibitor Concentration (50 percent kill): 242.6 µmol/L/48H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TXAPA9 245,281,2010 |
| In Vitro/Human, skin | Inhibitor Concentration (50 percent kill): 24.3 µmol/L/48H | In Vitro Toxicity Studies: Other assays | TXAPA9 245,281,2010 |
| In Vitro/Human, skin | Inhibitor Concentration (50 percent kill): 304.3 µmol/L/48H | In Vitro Toxicity Studies: Cell metabolic activity: Alamar Blue assay etc. | TIVIEQ 29,688,2015 |
| In Vitro/Human, skin | Inhibitor Concentration (30 percent kill): 280.5 µmol/L/48H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 29,688,2015 |
| In Vitro/Human, skin | Inhibitor Concentration (30 percent kill): 215.7 µmol/L/48H | In Vitro Toxicity Studies: Cell metabolic activity: Alamar Blue assay etc. | TIVIEQ 29,688,2015 |
| In Vitro/jrd | Inhibitor Concentration (50 percent kill): 4.45 mg/L/24H | In Vitro Toxicity Studies: Other assays | TIVIEQ 28,626,2014 |
| In Vitro/Mouse, fibroblast | Inhibitor Concentration (50 percent kill): 0.1 gm/L/24H | In Vitro Toxicity Studies: Cell membrane integrity: Cytoplasmic enzymes leakage (lactate dehydrogenase, ATP enzymes etc.) | TIVIEQ 27,174,2013 |
| In Vitro/Mouse, fibroblast | Inhibitor Concentration (50 percent kill): 0.1 gm/L/24H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 27,174,2013 |
| In Vitro/Rat, lung | Inhibitor Concentration (50 percent kill): 1258.9 µmol/L/1H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 32,347,2016 |
| In Vitro/Rat, lung | Inhibitor Concentration (50 percent kill): 5128.6 µmol/L/1H | In Vitro Toxicity Studies: Cell membrane integrity: Cytoplasmic enzymes leakage (lactate dehydrogenase, ATP enzymes etc.) | TIVIEQ 32,347,2016 |
| In Vitro/Rat, lung | Inhibitor Concentration (50 percent kill): 5754.4 µmol/L/1H | In Vitro Toxicity Studies: Cell protein synthesis | TIVIEQ 32,347,2016 |
| In Vitro/Rat, lung | Inhibitor Concentration (50 percent kill): 1621.8 µmol/L/1H | Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | TIVIEQ 32,347,2016 |
| inhalation/mouse | lowest published toxic concentration: 6 ppm/1.5H | Behavioral: Somnolence (general depressed activity) Lung, Thorax, or Respiration: Respiratory depression | TXCYAC 279,115,2011 |
| inhalation/rabbit | lowest published toxic concentration: 500 ppm | Eye: Conjunctiva irritation Lung, Thorax, or Respiration: Cough | VCVGK* -,404,1984 |
| inhalation/rat | lethal concentration (50 percent kill): 480 mg/m3/4H | EPASR* 8EHQ-1290-1008 | |
| inhalation/woman | lowest published toxic concentration: 200 ppb | Olfaction: Other olfaction effects | TOXID9 72,292,2003 |
| intraperitoneal/mouse | lethal dose (50 percent kill): 13900 µg/kg | IYKEDH 10,232,1979 | |
| intraperitoneal/rat | lethal dose (50 percent kill): 17900 µg/kg | IYKEDH 10,232,1979 | |
| intravenous/mouse | lethal dose (50 percent kill): 15400 µg/kg | OYYAA2 19,503,1980 | |
| intravenous/rat | lethal dose (50 percent kill): 9800 µg/kg | EPASR* 8EHQ-1290-1008 | |
| oral/duck | lethal dose (50 percent kill): 820 mg/kg | Behavioral: Somnolence (general depressed activity) Behavioral: Food intake (animal) | NTIS** OTS0526410-1 |
| oral/guinea pig | lethal dose (50 percent kill): 50 mg/kg | Behavioral: Altered sleep time (including change in righting reflex) Behavioral: Somnolence (general depressed activity) Behavioral: Excitement | GISAAA 52(3),77,1987 |
| oral/mouse | lethal dose (50 percent kill): 231 mg/kg | Lung, Thorax, or Respiration: Other changes Liver: Other changes Kidney, Ureter, and Bladder: Other changes | VCVGK* -,404,1984 |
| oral/mouse | lethal dose (50 percent kill): 100 mg/kg | OYYAA2 19,503,1980 | |
| oral/rat | lethal dose (50 percent kill): 140 mg/kg | Lung, Thorax, or Respiration: Other changes Liver: Other changes Kidney, Ureter, and Bladder: Other changes | VCVGK* -,404,1984 |
| oral/rat | lethal dose (50 percent kill): 134 mg/kg | OYYAA2 19,503,1980 | |
| skin/mouse | lowest published toxic dose: 1.25 mg/kg | Eye: Change in extra- ocular muscles | TXCYAC 279,115,2011 |
| skin/mouse | lethal dose (50 percent kill): >5840 mg/kg | Skin: After systemic exposure: Dermatitis, other | OYYAA2 12,11,1976 |
| skin/rabbit | lethal dose (50 percent kill): 560 µL/kg | UCDS** 11/4/1971 | |
| skin/rat | lethal dose (50 percent kill): >2500 mg/kg | Skin: After systemic exposure: Dermatitis, other | OYYAA2 12,11,1976 |
| subcutaneous/mouse | lethal dose (50 percent kill): >590 mg/kg | NIIRDN -,395,1995 | |
| subcutaneous/rat | lethal dose (50 percent kill): >750 mg/kg | NIIRDN -,395,1995 |
Other Multiple Dose Data and References
| Route/Organism | Dose | Effect | Reference |
|---|---|---|---|
| inhalation/mouse | lowest published toxic concentration: 16 ppm/6H/2W- intermittent | Olfaction: Other olfaction effects Lung, Thorax, or Respiration: Other changes Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field | NTPTR* NIH-93-3348 |
| inhalation/mouse | lowest published toxic concentration: 1000 ppb/6H/13W- intermittent | Olfaction: Other olfaction effects Nutritional and Gross Metabolic: Weight loss or decreased weight gain Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field | NTPTR* NIH-93-3348 |
| inhalation/mouse | lowest published toxic concentration: 250 ppb/6H/2Y- intermittent | Olfaction: Other olfaction effects Nutritional and Gross Metabolic: Weight loss or decreased weight gain | TOXID9 48,341,1999 |
| inhalation/rat | lowest published toxic concentration: 5 ppm/6H/2W- intermittent | Olfaction: Other olfaction effects Lung, Thorax, or Respiration: Other changes Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field | NTPTR* NIH-93-3348 |
| inhalation/rat | lowest published toxic concentration: 1000 ppb/6H/13W- intermittent | Olfaction: Other olfaction effects Nutritional and Gross Metabolic: Weight loss or decreased weight gain | NTPTR* NIH-93-3348 |
| inhalation/rat | lowest published toxic concentration: 500 ppb/6H/2Y- intermittent | Olfaction: Other olfaction effects Nutritional and Gross Metabolic: Weight loss or decreased weight gain Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field | TOXID9 48,341,1999 |
| oral/rat | lowest published toxic dose: 12376 mg/kg/2Y- continuous | Kidney, Ureter, and Bladder: Other changes in urine composition Kidney, Ureter, and Bladder: Changes in bladder weight Nutritional and Gross Metabolic: Weight loss or decreased weight gain | TOXID9 15,203,1995 |
| oral/rat | lowest published toxic dose: 54600 µg/kg/26W- intermittent | Liver: Fatty liver degeneration Nutritional and Gross Metabolic: Weight loss or decreased weight gain Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: True cholinesterase | GISAAA 52(3),77,1987 |
| oral/rat | lowest published toxic dose: 11410 mg/kg/7D- intermittent | Nutritional and Gross Metabolic: Weight loss or decreased weight gain | NTIS** OTS0535072 |
| oral/rat | lowest published toxic dose: 122.5 mg/kg/1W- continuous | Behavioral: Fluid intake | JTEHD6 61,107,2000 |
| oral/rat | lowest published toxic dose: 967 mg/kg/2W- continuous | Behavioral: Food intake (animal) | JTEHD6 61,107,2000 |
| oral/rat | lowest published toxic dose: 688.8 mg/kg/1W- continuous | Behavioral: Food intake (animal) | JTEHD6 61,107,2000 |
| oral/rat | lowest published toxic dose: 117.5 mg/kg/235D- intermittent | Endocrine: Changes in thymus weight Blood: Normocytic anemia Blood: Changes in other cell count (unspecified) | VCVGK* -,404,1994 |
| oral/rat | lowest published toxic dose: 1547 mg/kg/13W- intermittent | Kidney, Ureter, and Bladder: Urine volume decreased or anuria Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Multiple enzyme effects | TXCYAC 175,177,2002 |
| oral/rat | lowest published toxic dose: 9282 mg/kg/78W- intermittent | Kidney, Ureter, and Bladder: Urine volume decreased or anuria Kidney, Ureter, and Bladder: Changes in kidney weight Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Multiple enzyme effects | TXCYAC 175,177,2002 |
| skin/mouse | lowest published toxic dose: 0.375 mg/kg/3D- intermittent | Blood: Other changes | TXCYAC 279,115,2011 |
| skin/mouse | lowest published toxic dose: 3.75 mg/kg/3D- intermittent | Blood: Other changes Skin: After topical application: Cutaneous sensitization (experimental) | TXCYAC 279,115,2011 |
| subcutaneous/rat | lowest published toxic dose: 175 mg/kg/35D- continuous | Liver: Changes in liver weight Endocrine: Changes in spleen weight Blood: Normocytic anemia | OYYAA2 12,11,1976 |
Reviews
| Organization | Standard | Reference |
|---|---|---|
| American Conference of Governmental Industrial Hygienists (ACGIH) | Threshold Limit Value-ceiling concentration 0.05 ppm (sen) | DTLVS* TLV/BEI,2013 |
| American Conference of Governmental Industrial Hygienists (ACGIH) | Threshold Limit Value-Not classifiable as a human carcinogen | DTLVS* TLV/BEI,2013 |
| TOXICOLOGY REVIEW | DPIRDU 1(7),2,1981 | |
| TOXICOLOGY REVIEW | CRTXB2 22,143,1992 | |
| TOXICOLOGY REVIEW | JACTDZ 15,98,1996 | |
| TOXICOLOGY REVIEW | MUREAV 543,201,2003 | |
| TOXICOLOGY REVIEW | EMMUEG 39,69,2002 | |
| TOXICOLOGY REVIEW | MUREAV 589,136,2005 | |
| TOXICOLOGY REVIEW | HPCQA4 38,527,2007 | |
| TOXICOLOGY REVIEW | HUTOX* -,649,1996 | |
| TOXICOLOGY REVIEW | FCTOD7 47,1287,2009 | |
| TOXICOLOGY REVIEW | TOLED5 199,203,2010 | |
| TOXICOLOGY REVIEW | FCTOD7 55,596,2013 | |
| TOXICOLOGY REVIEW | RTOPDW 55,43,2009 | |
| TOXICOLOGY REVIEW | RTOPDW 56,54,2010 |
Standards and Regulations
| Organization | Standard | Reference |
|---|---|---|
| Environmental Protection Agency (EPA) Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) 1988 PESTICIDE SUBJECT TO REGISTRATION OR RE-REGISTRATION | FEREAC 54,7740,1989 | |
| Occupational Exposure Limit IN ARGENTINA, BULGARIA, COLOMBIA, JORDAN check ACGIH TLV; | ||
| Occupational Exposure Limit IN SINGAPORE, VIETNAM check ACGIH TLV | ||
| Occupational Exposure Limit-AUSTRALIA | ceiling concentration 0.1 ppm (0.41 mg/m3), JUL2008 | |
| Occupational Exposure Limit-AUSTRIA | MAK-TMW 0.1 ppm (0.4 mg/m3);KZW 0.1 ppm (0.4 mg/m3), sen, 2007 | |
| Occupational Exposure Limit-BELGIUM | short term exposure limit 0.05 ppm (0.21 mg/m3), MAR2002 | |
| Occupational Exposure Limit-DENMARK | ceiling concentration 0.2 ppm (0.8 mg/m3), MAY2011 | |
| Occupational Exposure Limit-FINLAND | ceiling concentration 0.1 ppm (0.42 mg/m3), NOV2011 | |
| Occupational Exposure Limit-FRANCE | VME 0.1 ppm (0.4 mg/m3), VLE 0.2 ppm (0.8 mg/m3), FEB2006 | |
| Occupational Exposure Limit-GERMANY | MAK 0.05 ppm (0.21 mg/m3), 2011 | |
| Occupational Exposure Limit-ICELAND | short term exposure limit 0.2 ppm (0.8 mg/m3), sen, NOV2011 | |
| Occupational Exposure Limit-JAPAN | ceiling concentration 0.03 ppm, a1 sen, s1 sen, MAY2012 | |
| Occupational Exposure Limit-KOREA | ceiling concentration 0.2 ppm (0.7 mg/m3), 2006 | |
| Occupational Exposure Limit-MEXICO | peak 0.2 ppm (0.7 mg/m3), 2004 | |
| Occupational Exposure Limit-NEW ZEALAND | short term exposure limit 0.05 ppm, sen, JAN2002 | |
| Occupational Exposure Limit-NORWAY | time-weighted average 0.2 ppm (0.8 mg/m3), JAN1999 | |
| Occupational Exposure Limit-PERU | short term exposure limit 0,05 ppm (0,2 mg/m3), JUL2005 | |
| Occupational Exposure Limit-RUSSIA | short term exposure limit 5 mg/m3, JUN2003 | |
| Occupational Exposure Limit-SWEDEN | ceiling concentration 0.2 ppm (0.8 mg/m3), Sen, JUN2005 | |
| Occupational Exposure Limit-SWITZERLAND | MAK-week 0.05 ppm (0.21 mg/m3), KZG-week 0.1 ppm (0.42 mg/m3), sen, JAN2011 | |
| Occupational Exposure Limit-THE NETHERLANDS | MAC-C 0.25 mg/m3, 2003 | |
| Occupational Exposure Limit-UNITED KINGDOM | time-weighted average 0.05 ppm (0.2 mg/m3);short term exposure limit 0.05 ppm (0.2 mg/m3), sen, OCT2007 |
NIOSH Documentation and Surveillance
| Organization | Standard | Reference |
|---|---|---|
| National Institute for Occupational Safety and Health (NIOSH) Recommended Exposure Level TO GLUTARALDEHYDE-air | ceiling concentration 0.2 ppm | NIOSH* DHHS #92-100,1992 |
| National Occupational Exposure Survey 1983 | Hazard Code 84349; Number of Industries 35; Total Number of Facilities 9475; Number of Occupations 63; Total Number of Employees Exposed 367330; Total Number of Female Employees Exposed 265564 | |
| National Occupational Hazard Survey 1974 | Hazard Code 84349; Number of Industries 11; Total Number of Facilities 2069; Number of Occupations 25; Total Number of Employees Exposed 12954 |
Status in Federal Agencies
Page last reviewed: November 16, 2018
Content
source: National Institute for Occupational Safety and Health